Skip to content
Review Open access

Intra-Host Evolution of SARS-CoV-2 During Persistent Infection of Pediatric COVID-19 Patients

Aug 2026 · Journal of the Pediatric Infectious Diseases Society · 0 citations

TL;DR

Clinical characteristics and intra-host viral evolution in pediatric patients with prolonged COVID-19 are examined, comparing immunocompetent and immunocompromised hosts, highlighting the need for continued genomic surveillance in vulnerable pediatric populations.

Abstract

Children typically experience milder SARS-CoV-2 infection than adults, yet a subset—especially those with immune compromise—develop persistent infection. This study examined clinical characteristics and intra-host viral evolution in pediatric patients with prolonged COVID-19, comparing immunocompetent and immunocompromised hosts. Residual nasopharyngeal specimens from patients <20 years old with ≥3 samples ≤90 days apart underwent qRT-PCR confirmation and whole-genome sequencing using tiled amplicon Illumina methods. Demographic, clinical, and immune-status data were extracted through chart review. Viral load trajectories and longitudinal genomic changes were analyzed. Sixteen patients met inclusion criteria: 5 immunocompetent and 11 immunocompromised children. Groups showed similar demographic distributions (mean ages 6 vs. 9.2 years; 60% vs. 64% male; 60% vs. 45% Hispanic). Vaccination was rare, with all immunocompetent and 82% of immunocompromised patients unvaccinated. COVID-19 treatment differed markedly: 1 immunocompetent (20%) versus 8 immunocompromised patients (73%) received therapies including monoclonal antibodies or remdesivir. Clinical severity varied, with immunocompetent children largely asymptomatic or managed as outpatients, whereas immunocompromised children more frequently required hospitalization (28%), ICU care (9%), or died (18%). Despite this, WHO severity scores were similar (2.4 vs. 2.2). Sequencing yielded 15 isolates from immunocompetent and 35 isolates from immunocompromised patients. Viral loads generally declined over time, though several immunocompromised children demonstrated prolonged high viral loads. Longitudinal sequencing identified intra-host viral diversification in both groups, including nonsynonymous Spike mutations and minority variants associated with immune escape. Some immunocompromised patients accumulated mutations at positions linked to therapeutic resistance. Pediatric persistent SARS-CoV-2 infection is associated with measurable intra-host viral evolution. Immunocompromised children demonstrated longer infection duration, more frequent treatment exposure, and extended viral shedding, creating conditions that may favor viral diversification. These findings highlight the need for continued genomic surveillance in vulnerable pediatric populations.

Read PDF

Similar papers

Open access Aug 2026

Immunogenicity of COVID-19 Vaccines in Patients Under Immunosuppressive Therapy: Insights Into Antibody Response and Gender Differences

While most ARD patients demonstrated a detectable response, gender appeared to influence antibody levels, with females exhibiting a weaker response, which is consistent with the literature suggesting that vaccine efficacy may be reduced in immunocompromised populations.

Reza Farrokhseresht, Hanieh Roghanian, H. Samimagham et al. · 0 citations
Open access Sep 2026

Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children

Persistent symptoms following acute viral respiratory infections are increasingly recognized in children. While post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; long COVID) have been extensively studied, whether comparable post-acute morbidity occurs after other major respiratory viru...

F. Bedir, Velit Demir · 0 citations
Open access Sep 2026

Respiratory Syncytial Virus infections in immunosuppressed adults <65 years old: a comparative analysis with Influenza and SARS-CoV2

ObjectivesRespiratory Syncytial Virus (RSV) vaccine policies have varied globally since their approval in 2023. In the UK, policy has adapted in line with National evidence generation such that from Autumn 2026 at-risk persons [≥]65 years old will become eligible for vaccination. Immunosuppressed persons <65 years will...

M. Danysz, E. Barnes, S. Lim et al. · 0 citations
Open access Sep 2026

Clinical Characteristics of Vaccinated and Unvaccinated Patients Who Died from COVID-19: A Retrospective Comparative Study

Background: Fatal COVID-19 cases continued to occur after the introduction of vaccination, particularly among older adults and individuals with chronic comorbidities. This study aimed to describe and compare the demographic and clinical characteristics of vaccinated and unvaccinated adults who died from COVID-19. Metho...

Yeşim Işler, Halil Kaya, Abdullah Furkan Ortabük et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.